Zymride M 1 Forte Tablet PR is a combination oral antidiabetic medication containing Glimepiride 1mg and Metformin 1000mg, formulated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily reduces hepatic glucose production and increases peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. This synergistic combination is indicated for patients inadequately controlled on diet and exercise alone or those requiring dual therapy to achieve optimal blood glucose levels. The prolonged-release formulation ensures a steady release of active ingredients, promoting better tolerability and adherence by minimizing gastrointestinal side effects commonly associated with Metformin. Zymride M 1 Forte Tablet PR should be administered under medical supervision, with dosage adjustments based on therapeutic response and renal function. It is contraindicated in patients with severe renal impairment, metabolic acidosis, or hypersensitivity to its components. Regular monitoring of blood glucose, renal function, and potential adverse effects such as hypoglycemia is essential. This combination therapy offers an effective approach to glycemic control, reducing the risk of diabetes-related complications when used as part of a comprehensive diabetes management plan.